Arena Pharmaceuticals Files European Marketing Authorization for Lorcaserin for Weight Control

1 min read

The FINANCIAL — Arena Pharmaceuticals announced the filing of a Marketing Authorization Application with the European Medicines Agency for lorcaserin, an investigational drug candidate intended for weight control, including weight loss and maintenance of weight loss, in patients who are obese or patients who are overweight and have at least one weight-related co-morbid condition.


According to Arena Pharmaceuticals, Arena expects the EMA will accept the filing later this month and confirm the filing is sufficiently complete to permit a substantive review.


"With rates of obesity tripling in many European countries over the last thirty years, there is a substantial unmet need for new treatments to manage weight," said Jack Lief, Arena's President and Chief Executive Officer. "We look forward to working with the EMA and our Rapporteur and Co-rapporteur during this centralized review process and to the potential approval of lorcaserin in E.U. member countries."



See also  NIH study finds high BMI and obesity raise infection risk, but asthma does not

Leave a Reply